tarlatamab + AMG 404

**tarlatamab + AMG 404** is an investigational combination therapy studied primarily for the treatment of small cell lung cancer (SCLC). Tarlatamab (AMG 757) is a half-life extended bispecific T-cell engager (BiTE) molecule that binds both delta-like protein 3 (DLL3), a target highly expressed in SCLC tumor cells, and CD3 on T cells, thereby redirecting T-cell cytotoxicity toward DLL3-positive tumor cells. AMG 404 is a fully human monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor, functioning as a checkpoint inhibitor to block the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby augmenting T-cell responses against tumors. The combination is designed to enhance antitumor activity by addressing both targeted tumor cell killing and overcoming immunosuppressive mechanisms in the tumor microenvironment. The combination is being developed and tested by Amgen in phase 1b clinical trials in adults with SCLC who have progressed after platinum-based chemotherapy[1][2][3][4].

Other names

tarlatamab + AMG 404